Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Atossa Genetics Inc. (ATOS : NSDQ)
 
 • Company Description   
Atossa Genetics Inc. is a healthcare company focused on the development and marketing of cellular and molecular diagnostic risk assessment products for breast cancer. The Company's diagnostic tests consist of medical devices which can collect fluid samples from the breast milk ducts. It is also conducting research on the treatment of pre-cancerous cells by using its FDA-cleared microcatheters to deliver, directly into the milk ducts, anti-cancer drugs that can be used to treat the pre-cancerous lesions. Atossa Genetics Inc. is headquartered in Seattle, WA.

Number of Employees: 8

 
 • Price / Volume Information   
Yesterday's Closing Price: $7.15 Daily Weekly Monthly
20 Day Moving Average: 23,814,960 shares
Shares Outstanding: 120.82 (millions)
Market Capitalization: $863.89 (millions)
Beta: 2.19
52 Week High: $8.48
52 Week Low: $0.81
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 129.17% 126.69%
12 Week 238.86% 217.38%
Year To Date 652.63% 566.44%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
107 SPRING STREET
-
SEATTLE,WA 98104
USA
ph: 206-325-6086
fax: 206-430-1288
scottg@coreir.com http://www.atossagenetics.com
 
 • General Corporate Information   
Officers
Steven C. Quay - Chairman; Chief Executive Officer and President
Kyle Guse - Chief Financial Officer; General Counsel and Secre
Richard I. Steinhart - Director
Shu-Chih Chen - Director
Gregory Weaver - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED INSTRUMENTS
Sector: Medical
CUSIP: 04962H506
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/21
Next Expected EPS Date: 08/12/21
Share - Related Items
Shares Outstanding: 120.82
Most Recent Split Date: 4.00 (0.08:1)
Beta: 2.19
Market Capitalization: $863.89 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/12/21  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 6.21
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 87.50%
vs. Previous Quarter: 95.51%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/21 - -50.20
12/31/20 - -166.12
09/30/20 - -130.58
ROA
03/31/21 - -44.60
12/31/20 - -117.07
09/30/20 - -108.14
Current Ratio
03/31/21 - 102.27
12/31/20 - 2.73
09/30/20 - 7.23
Quick Ratio
03/31/21 - 102.27
12/31/20 - 2.73
09/30/20 - 7.23
Operating Margin
03/31/21 - -
12/31/20 - -
09/30/20 - -
Net Margin
03/31/21 - -
12/31/20 - -
09/30/20 - -
Pre-Tax Margin
03/31/21 - -
12/31/20 - -
09/30/20 - -
Book Value
03/31/21 - 1.15
12/31/20 - 0.37
09/30/20 - 0.89
Inventory Turnover
03/31/21 - -
12/31/20 - -
09/30/20 - -
Debt-to-Equity
03/31/21 - 0.00
12/31/20 - 0.00
09/30/20 - 0.00
Debt-to-Capital
03/31/21 - 0.00
12/31/20 - 0.00
09/30/20 - 0.00
 

Powered by Zacks Investment Research ©